

Case IPR2016-00111

Declaration of Michael J. Akers, Ph.D. Under 37 C.F.R. § 1.68 in Support of
Petition for *Inter Partes* Review of U.S. Patent No. 8,895,756

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FRESENIUS KABI USA, LLC,
Petitioner

v.

CEPHALON, INC.,
Patent Owner

Case IPR2016-00111
Patent No. 8,895,756

DECLARATION OF MICHAEL J. AKERS, Ph.D., UNDER 37 C.F.R. § 1.68
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S.
PATENT NO. 8,895,756

Mail Stop: Patent Board
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	BACKGROUND AND QUALIFICATIONS	1
III.	MATERIALS CONSIDERED FOR THIS DECLARATION	6
IV.	OVERVIEW OF THE '756 PATENT	7
V.	LEVEL OF ORDINARY SKILL IN THE PERTINENT ART	8
VI.	BROADEST REASONABLE CONSTRUCTION	8
VII.	UNDERSTANDING OF THE LAW.....	8
VIII.	SCOPE AND CONTENT OF THE PRIOR ART	10
	A. The Ribomustin® Product Monograph	11
	B. Alexander	12
	C. Sauerbier	13
	D. Teagarden.....	15
	E. Maas	17
	F. Sullivan	17
	G. DeLuca.....	17
IX.	DETAILED ANALYSIS	18
	A. Summary of Opinion.....	19
	B. One of Ordinary Skill in the Art Would Have Been Motivated to Combine the Ribomustin® Product Monograph with Alexander or Sauerbier With a Reasonable Expectation of Success to Obtain a Lyophilized Formulation of Bendamustine Hydrochloride and Mannitol	

	With More Desirable Cake Characteristics, Including a Faster Reconstitution Time, Than Ribomustin®.....	20
C.	One of Ordinary Skill in the Art Would Have Been Motivated to Combine the Ribomustin® Product Monograph with Alexander or Sauerbier and Teagarden With a Reasonable Expectation of Success to Obtain a Lyophilized Formulation of Bendamustine Hydrochloride and Mannitol With More Desirable Cake Characteristics, Including a Faster Reconstitution Time, Than Ribomustin®.....	27
D.	One of Ordinary Skill in the Art Would Have Been Motivated to Combine the Ribomustin® Product Monograph with Alexander or Sauerbier, Teagarden and DeLuca With a Reasonable Expectation of Success to Obtain a Lyophilized Formulation of Bendamustine Hydrochloride and Mannitol With More Desirable Cake Characteristics, Including a Faster Reconstitution Time, Than Ribomustin®.....	30
E.	One of Ordinary Skill in the Art Would Have Been Motivated to Combine Maas and the Ribomustin® Product Monograph with Alexander or Sauerbier and Teagarden With a Reasonable Expectation of Success to Obtain a Lyophilized Formulation of Bendamustine Hydrochloride and Mannitol With More Desirable Cake Characteristics and a Better Impurity Profile Than Ribomustin®.....	36
X.	SUPPLEMENTATION.....	41
XI.	CONCLUSION.....	42

I, Michael J. Akers, Ph.D. hereby declare as follows:

I. INTRODUCTION

1. I have been retained as an expert witness on behalf of Fresenius Kabi USA, LLC (“Fresenius”) for the above-captioned Petition for *Inter Partes* Review (“IPR”) of U.S. Patent No. 8,895,756 (“the ’756 patent”). I have been asked to provide my opinions regarding the motivation to combine certain prior art references from the perspective of one of ordinary skill in the art at the time of the alleged invention.

2. I am being compensated at a rate of \$300 per hour for my study and testimony in this matter. I am also being reimbursed for reasonable and customary expenses associated with my work and testimony in this investigation. My compensation is not contingent on the outcome of this matter or the specifics of my testimony.

II. BACKGROUND AND QUALIFICATIONS

3. I received a Bachelor of Arts degree in Biology from Wabash College in 1968. I received my Ph.D. in Pharmaceutics from the University of Iowa in 1972. I have over 40 years of experience in pharmaceutical formulation and development, with a special focus on formulation of lyophilized and parenteral products.

4. From 1974-1977, I was the Senior Scientist and Head of the Preformulation Research Section of Alcon Laboratories. At Alcon, I personally participated in the formulation development of numerous sterile products, including Balanced Salt Solution (BSS) 500 ml; BSS PLUS Intraocular Irrigating Solution; Natcyn (Natamycin) Ophthalmic Suspension; ZOLYSE (alpha-chymotrypsin) Solution; DENDRID (idoxuridine) Ointment; EPINAL (epinephryl borate) Ophthalmic Solution; and TOBREX (tobramycin) Ophthalmic Solution. I also contributed to numerous IND and NDA submissions.

5. For nearly 20 years, I held various positions at Eli Lilly and Company (“Lilly”), including Head of the Parenteral and Liquid Product Department. At Lilly, I personally participated in the formulation and development of at least 3 lyophilized products, and was the lead scientist on numerous Lilly parenteral compounds including both proteins and small molecules. I was also responsible for QC activities for all (>200) Lilly-marketed parenteral products, including insulin vials and freeze-dried and powder filled items. I personally participated in the preparation of NDAs for Glucagon Emergency Kit, Tazidime[®], Keftab[®], Keflet[®], Humulin[®] Cartridges, Vancocin[®] Frozen Minibag, and Gemzar[®].

6. From 2002 through my retirement in 2012, I became Senior Director of Pharmaceutical Research and Development at Baxter Biopharma Solutions

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.